Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lactation suppression and puerperal fever.

O D Almeida, D Z Kitay

    American Journal of Obstetrics and Gynecology
    |April 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Bromocriptine mesylate (Parlodel) effectively prevents puerperal fever in women not choosing to breast-feed. Early administration within 18 hours of delivery ensures complete prevention of fever related to engorgement.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Re: JSLS 2005;9: 463-465 Heated, humidified CO2 gas is unsatisfactory for awake laparoscopy.

    JSLS : Journal of the Society of Laparoendoscopic Surgeons·2007
    Same author

    Current state of office laparoscopic surgery.

    The Journal of the American Association of Gynecologic Laparoscopists·2000
    Same author

    Small trocar perforation of the small bowel: a case report.

    JSLS : Journal of the Society of Laparoendoscopic Surgeons·1999
    Same author

    Office microlaparoscopy under local anesthesia in the diagnosis and treatment of chronic pelvic pain.

    The Journal of the American Association of Gynecologic Laparoscopists·1998
    Same author

    Appendectomy under local anaesthesia following conscious pain mapping with microlaparoscopy.

    Human reproduction (Oxford, England)·1998
    Same author

    Conscious pain mapping.

    The Journal of the American Association of Gynecologic Laparoscopists·1997
    Same journal

    Early patient removal of urinary catheters after urogynecologic surgery, a randomized trial.

    American journal of obstetrics and gynecology·2026
    Same journal

    Standard vs. Lower Pressure Pneumoperitoneum in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial.

    American journal of obstetrics and gynecology·2026
    Same journal

    Association of Surgical Approach with Oncologic Outcomes in Low-Risk Cervical Cancer.

    American journal of obstetrics and gynecology·2026
    Same journal

    Trends in Infertility Treatments by Race, Ethnicity, Socioeconomic Status, and Region in U.S. Birth Certificates from Live Births: 2011-2022.

    American journal of obstetrics and gynecology·2026
    Same journal

    Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    Same journal

    Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

    American journal of obstetrics and gynecology·2026
    See all related articles

    Area of Science:

    • Obstetrics and Gynecology
    • Pharmacology
    • Reproductive Medicine

    Background:

    • Puerperal fever, a significant postpartum complication, can arise from various causes including breast engorgement.
    • Suppression of lactation is desired by some postpartum women, necessitating safe and effective interventions.

    Purpose of the Study:

    • To evaluate the efficacy of bromocriptine mesylate (Parlodel) in preventing puerperal fever among women who elect not to breast-feed.
    • To determine the impact of bromocriptine mesylate timing on fever prevention.

    Main Methods:

    • A prospective, randomized, double-blind study involving 75 puerperal women was conducted.
    • Participants received either bromocriptine mesylate (Parlodel) or a placebo.
    • Incidence of puerperal fever, including fever due to breast engorgement and infectious processes, was recorded.

    Related Experiment Videos

    Main Results:

    • Bromocriptine mesylate (Parlodel) demonstrated an 87.9% prevention rate for puerperal fever.
    • Fever incidence in the placebo group was 18.6%, with 13.3% attributed to breast engorgement and 5.3% to infection.
    • When administered within 18 hours postpartum, bromocriptine mesylate achieved 100% prevention of physiologic puerperal fever.

    Conclusions:

    • Bromocriptine mesylate (Parlodel) is a highly effective agent for preventing puerperal fever in non-breast-feeding women.
    • Early intervention with bromocriptine mesylate significantly enhances its prophylactic effect against postpartum fever, particularly that associated with breast engorgement.